Overview

The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the contribution of endogenous Glucagon-like peptide 1 (GLP-1) to the postprandial secretion of insulin and glucagon and the incretin effect in healthy subjects and patients with type 2 diabetes mellitus (T2DM).
Phase:
Phase 1
Details
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Treatments:
Glucagon
Glucagon-Like Peptide 1